Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:13 AM
Ignite Modification Date:
2025-12-25 @ 2:13 AM
NCT ID:
NCT02587260
Eligibility Criteria:
Inclusion Criteria:
* Patients older than 18 years.
* Patients who experienced an Acute Coronary Syndrome (including STEMI or NSTEMI) at least 30 days before.
* Patients on ongoing treatment for at least 30 days with dual anti-platelet therapy consisting of aspirin, at doses of 75-160 mg daily and one commercially available P2Y12 oral inhibitor , including ticagrelor, clopidogrel or prasugrel.
* Patients who remained free from bleeding (defined as BARC type 2 or greater) or ischemic recurrences.
* Signed informed consent All inclusion criteria are required.
Exclusion Criteria:
* Administration of fibrinolytics or glycoprotein IIb/IIIa inhibitors in the previous 30 days.
* Major surgery within 30 days or any planned surgical or percutaneous intervention.
* Active bleeding or previous clinical relevant bleeding or stroke in the last 6 months.
* Previous transient ischemic attack or intracranial bleeding.
* Thrombocytopenia.
* Oral anticoagulant therapy.
* Vasculitis or any know immunological disorder.
* Severe hepatic failure.
* Uncontrolled hypertension (systolic or diastolic arterial pressure \>180 mmHg or 120, respectively, despite medical therapy).
* Known intolerance to aspirin or to clopidogrel or prasugrel or ticagrelor.
* Limited life expectancy, e.g. neoplasms, others.
* Inability to obtain informed consent.
* Pregnancy.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02587260
Study Brief:
Protocol Section:
NCT02587260